Novel antibacterial agents for the treatment of serious Gram-positive infections

Author： Abbanat Darren   Macielag Mark   Bush Karen  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.12, Iss.3, 2003-03, pp. : 379-399

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Novel agents for the treatment of resistant Gram-positive infections

By Woodford Neil  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 2, 2003-02 ,pp. : 117-137

Informa Healthcare

Access to resources Recommend Favorite

Telavancin: a novel lipoglycopeptide for serious Gram-positive infections

By Laohavaleeson Somvadee   Kuti Joseph L   Nicolau David P  

Expert Opinion on Investigational Drugs, Vol. 16, Iss. 3, 2007-03 ,pp. : 347-357

Informa Healthcare

Access to resources Recommend Favorite

Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia

By Rubinstein Ethan   Corey G Ralph   Stryjewski Martin E   Kanafani Zeina A  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 17, 2011-12 ,pp. : 2737-2750

Informa Healthcare

Access to resources Recommend Favorite

Daptomycin - a novel antibacterial in the fight against resistant Gram-positive infections

By  

Inpharma, Vol. 1, Iss. 1286, 2001-01 ,pp. : 10-11

Adis International

Access to resources Recommend Favorite

Daptomycin: a novel agent for Gram-positive infections

By Tally F.P.   Zeckel M.   Wasilewski M.M.   Carini C.   Berman C.L.   Drusano G.L.   Oleson F.B.  

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 8, 1999-08 ,pp. : 1223-1238

Informa Healthcare

Access to resources Recommend Favorite